title: Comparison of three days' therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection.
abstract: The clinical and bacteriologic efficacy of 3 days of cefcanel daloxate therapy, compared with 3 days of amoxicillin for the treatment of acute uncomplicated urinary tract infection was compared in a prospective randomized double-blind multicentre study. 400 subjects were randomized to receive cefcanel daloxate and 199 to receive amoxicillin. 166 (77%) of 215 evaluable cefcanel daloxate subjects and 72 (77%) of 94 evaluable amoxicillin subjects evidenced bacteriologic elimination at short-term follow-up, while in 149 (69%) and 67 (71%), respectively, clinical symptoms disappeared. At long-term follow-up, 150 (70%) cefcanel daloxate and 65 (69%) amoxicillin subjects evidenced bacteriological elimination, while in 150 (70%) and 61 (65%), clinical symptoms disappeared. There were no significant differences in outcome between the 2 therapeutic regimens. Adverse events were similar in the 2 groups. In additional analyses, antimicrobial efficacy diminished significantly with increasing age, pretherapy in vitro susceptibility was significantly associated with bacteriological failure at the short-term visit, and subjects with low quantitative counts pretherapy had clinical outcomes similar to those with quantitative counts > or = 10(5) cfu/ml at the short-term outcome. These data suggest that cefcanel daloxate and amoxicillin are comparable as regards efficacy and adverse effects for 3-day therapy of acute uncomplicated urinary tract infection. The observed cure rates, however, are lower than those reported for other agents such as trimethoprim/sulfamethoxazole or quinolones for short course therapy.
authors.affiliation: Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
authors.forename: L E
authors.initials: LE
authors.lastname: Nicolle
authors.forename: A I
authors.initials: AI
authors.lastname: Hoepelman
authors.forename: M
authors.initials: M
authors.lastname: Floor
authors.forename: J
authors.initials: J
authors.lastname: Verhoef
authors.forename: K
authors.initials: K
authors.lastname: Norgard
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D002511:Cephalosporins; D000658:Amoxicillin; C045380:cefcanel daloxate